Clinical TrialJul 17, 2026, 08:03 AM
SL Science presents preclinical glioblastoma treatment data
AI Summary
SL Science Holding Limited announced successful exhibition and participation at WCP 2026, where it presented highly promising preclinical research on a novel treatment for glioblastoma (GBM). The research, a collaboration with Taipei Medical University, JY BioMed, and HeXun Biosciences, showcased the power of gamma delta (γδ) T cells in eliminating glioblastoma in preclinical studies. Key findings included complete tumor eradication by day 26 at the highest dose, dose-dependent success, and a clean safety profile, highlighting the potential of their γδ T-cell platform for challenging solid tumors.
Key Highlights
- Preclinical studies showed complete glioblastoma tumor elimination by day 26 post-treatment at highest dose.
- Gamma delta (γδ) T cell treatment demonstrated dose-dependent success in preclinical models.
- The treatment exhibited a clean safety profile with no major adverse effects in the study.
- Research was a joint effort with Taipei Medical University, JY BioMed, and HeXun Biosciences.
- Findings were presented at the 2026 World Congress of Basic and Clinical Pharmacology (WCP 2026).
Price Impact
More from SLBT